Additional label warnings that may impact initiation decisions include caution in patients with severe gastrointestinal disease or gastroparesis (not recommended), history of pancreatitis, and gallbladder disease
SELECT (CV outcomes): The landmark 17,604-patient trial demonstrating 20% MACE reduction in overweight/obese adults with established CVD but without diabetes -- establishing semaglutide as the first anti-obesity medication with proven cardiovascular benefit
Fat tissue produces the hormone leptin, which helps control hunger
Her case was one of the first nine consolidated into MDL 3094
Consistent weekly injections are crucial for semaglutide to be effective
Serious Risks Glucagon-like peptide-1 receptor agonists (GLP1-RAs), including semaglutide, are linked to an increased risk of serious medical conditions, including: Pancreatitis Gallbladder problems Kidney injury Allergic reactions Pulmonary aspiration during anesthesia Mixing Semaglutide and Alcohol There is no direct interaction between alcohol and semaglutide